Patient characteristics and leukemia main features at diagnosis in the screening cohort
| Variable . | Total patients . | CD371pos patients . | CD371neg patients . | P value . | |||
|---|---|---|---|---|---|---|---|
| n . | % . | n . | % . | n . | % . | ||
| Total | 843 | 100 | 76 | 9.0 | 767 | 91.0 | |
| Age, y | < .001 | ||||||
| 1-9 | 676 | 80.2 | 41 | 54.0 | 635 | 82.8 | |
| 10-17 | 167 | 19.8 | 35 | 46.0 | 132 | 17.2 | |
| Sex | .770 | ||||||
| Male | 457 | 54.2 | 40 | 52.6 | 417 | 54.4 | |
| Female | 386 | 45.8 | 36 | 47.4 | 350 | 45.6 | |
| WBC count | .080 | ||||||
| <50 × 109/L | 734 | 87.1 | 71 | 93.4 | 663 | 86.5 | |
| 50-99 × 109/L | 63 | 7.5 | 1 | 1.3 | 62 | 8.1 | |
| ≥100 × 109/L | 45 | 5.3 | 4 | 5.3 | 41 | 5.4 | |
| DNA index | < .001 | ||||||
| <0.8 | 7 | 0.8 | 0 | 7 | 0.9 | ||
| ≥0.8, <1.00 | 0 | 0 | 0 | ||||
| 1.00 | 511 | 61.2 | 66 | 88.0 | 445 | 58.6 | |
| >1.00, <1.16 | 111 | 13.3 | 2 | 2.7 | 109 | 14.3 | |
| ≥1.16 | 206 | 24.7 | 7 | 9.3 | 199 | 26.2 | |
| Fusion genes | |||||||
| ETV6::RUNX1 | 191 | 23.1 | 1 | 1.4 | 190 | 25.2 | < .001 |
| TCF3::PBX1 | 30 | 3.7 | 0 | 0.0 | 30 | 4.1 | .100 |
| KMT2A::AFF1 | 6 | 0.7 | 1 | 1.4 | 5 | 0.7 | .430 |
| Immunophenotype at diagnosis (EGIL) | < .001 | ||||||
| BI-ALL | 22 | 2.6 | 10 | 13.2 | 12 | 1.6 | |
| BII-ALL | 635 | 75.3 | 66 | 86.8 | 569 | 74.2 | |
| BIII-ALL | 186 | 22.1 | 0 | 0.0 | 186 | 24.2 | |
| Ambiguous leukemia | |||||||
| BAL (EGIL) | 7 | 0.8 | 1 | 1.3 | 6 | 0.8 | .490 |
| MPAL (WHO) | 24 | 2.8 | 3 | 4.0 | 21 | 2.7 | .540 |
| Variable . | Total patients . | CD371pos patients . | CD371neg patients . | P value . | |||
|---|---|---|---|---|---|---|---|
| n . | % . | n . | % . | n . | % . | ||
| Total | 843 | 100 | 76 | 9.0 | 767 | 91.0 | |
| Age, y | < .001 | ||||||
| 1-9 | 676 | 80.2 | 41 | 54.0 | 635 | 82.8 | |
| 10-17 | 167 | 19.8 | 35 | 46.0 | 132 | 17.2 | |
| Sex | .770 | ||||||
| Male | 457 | 54.2 | 40 | 52.6 | 417 | 54.4 | |
| Female | 386 | 45.8 | 36 | 47.4 | 350 | 45.6 | |
| WBC count | .080 | ||||||
| <50 × 109/L | 734 | 87.1 | 71 | 93.4 | 663 | 86.5 | |
| 50-99 × 109/L | 63 | 7.5 | 1 | 1.3 | 62 | 8.1 | |
| ≥100 × 109/L | 45 | 5.3 | 4 | 5.3 | 41 | 5.4 | |
| DNA index | < .001 | ||||||
| <0.8 | 7 | 0.8 | 0 | 7 | 0.9 | ||
| ≥0.8, <1.00 | 0 | 0 | 0 | ||||
| 1.00 | 511 | 61.2 | 66 | 88.0 | 445 | 58.6 | |
| >1.00, <1.16 | 111 | 13.3 | 2 | 2.7 | 109 | 14.3 | |
| ≥1.16 | 206 | 24.7 | 7 | 9.3 | 199 | 26.2 | |
| Fusion genes | |||||||
| ETV6::RUNX1 | 191 | 23.1 | 1 | 1.4 | 190 | 25.2 | < .001 |
| TCF3::PBX1 | 30 | 3.7 | 0 | 0.0 | 30 | 4.1 | .100 |
| KMT2A::AFF1 | 6 | 0.7 | 1 | 1.4 | 5 | 0.7 | .430 |
| Immunophenotype at diagnosis (EGIL) | < .001 | ||||||
| BI-ALL | 22 | 2.6 | 10 | 13.2 | 12 | 1.6 | |
| BII-ALL | 635 | 75.3 | 66 | 86.8 | 569 | 74.2 | |
| BIII-ALL | 186 | 22.1 | 0 | 0.0 | 186 | 24.2 | |
| Ambiguous leukemia | |||||||
| BAL (EGIL) | 7 | 0.8 | 1 | 1.3 | 6 | 0.8 | .490 |
| MPAL (WHO) | 24 | 2.8 | 3 | 4.0 | 21 | 2.7 | .540 |
Data not available: WBC count: 1 patient; DNA index: 8 patients; BAL: 2 patients. Bold values correspond to P < .05.
BAL, biphenotypic acute leukemia; MPAL, mixed-phenotype acute leukemia; neg, negative; pos, positive; WBC, white blood cell; WHO, World Health Organization.